<DOC>
	<DOCNO>NCT02429440</DOCNO>
	<brief_summary>Clinical Phase I/II study investigate feasibility tolerability synthetic adjuvant peptide immunisation combination immune adjuvant ( granulocyte macrophage colony stimulate factor ; Montanide ISA-51 ) patient advance renal cell cancer ( RCC ) .</brief_summary>
	<brief_title>Adjuvant Antigen Specific Immunotherapy Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>Advanced renal cell carcinoma clinical stage T3 T4 , N0 , M0 N+ , M0 M1 ( complete metastasectomy ) ECOG performance status 0 1 age &gt; 18 year least 4 week since last administration radiation chemotherapy Serum level bilirubin &lt; 2 mg/dl , creatinine &lt; 2mg/dl detectable distant metastasis radiological imaging ( M1 ) patient unable consent severe cardiopulmonary disorder ( NYHA &gt; = 3 ) presence secondary malignancy Immunosuppressive medication ( last application glucocorticoid &gt; 4 week ) seizure pregnancy simultaneous participation active passive immunisation treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>